rasagiline has been researched along with Cognition Disorders in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Deng, L; Li, J; Qin, X; Sun, H; Tang, R; Yi, L; Zhang, C; Zhang, L; Zhang, Z; Zheng, J; Zhou, H | 1 |
| Buchanan, RW; Gold, JM; Gorelick, DA; Keller, WR; Kelly, DL; McMahon, RP; Waltz, JA; Weiner, E | 1 |
| Hanagasi, HA | 1 |
| Amit, T; Badinter, F; Bar-Am, O; Weinreb, O; Youdim, MB | 1 |
| Fossati, C; Stocchi, F; Torti, M | 1 |
| Crispin, A; Hensler, M; Lorenzl, S; Nuebling, G; Paul, S; Zwergal, A | 1 |
| Cakmur, R; Emre, M; Feyzioglu, A; Gunal, DI; Gurvit, H; Hanagasi, HA; Horozoglu, H; Sahin, HA; Tuncer, N; Unsalan, P; Yener, GG | 1 |
| Tarrants, ML; Zagmutt, FJ | 1 |
| Pagonabarraga, J; RodrÃguez-Oroz, MC | 1 |
| Blaugrund, E; Cohen, S; Fine, T; Litinetsky, L; Mayk, A; Nyska, A; Speiser, Z | 1 |
| Cohen, S; Levy, R; Speiser, Z | 1 |
3 review(s) available for rasagiline and Cognition Disorders
| Article | Year |
|---|---|
Rasagiline for the treatment of Parkinson's disease: an update.
Topics: Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Cognition Disorders; Drug Therapy, Combination; Fatigue; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Quality of Life | 2015 |
Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
Topics: Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Cross-Sectional Studies; Databases, Bibliographic; Fatigue; Female; Gastrointestinal Diseases; Humans; Indans; Indoles; Logistic Models; Male; Parkinson Disease; Patient Dropouts; Pramipexole; Sleep Wake Disorders; Treatment Outcome | 2012 |
[Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Topics: Antiparkinson Agents; Attention; Clinical Trials as Topic; Cognition Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Executive Function; Fatigue; Headache; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Motor Activity; Multicenter Studies as Topic; Nausea; Neuroprotective Agents; Parkinson Disease; Severity of Illness Index | 2013 |
5 trial(s) available for rasagiline and Cognition Disorders
| Article | Year |
|---|---|
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Topics: Adult; Aged; Antiparkinson Agents; Asian People; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease | 2013 |
Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.
Topics: Adult; Cognition Disorders; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia | 2015 |
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Topics: Cognition Disorders; Double-Blind Method; Humans; Indans; Neuroprotective Agents; Parkinson Disease | 2015 |
PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.
Topics: Aged; Area Under Curve; Cognition Disorders; Depression; Disease Progression; Double-Blind Method; Electrocardiography; Executive Function; Female; Follow-Up Studies; Humans; Indans; Male; Mental Status Schedule; Middle Aged; Monoamine Oxidase Inhibitors; Postural Balance; Sensation Disorders; Supranuclear Palsy, Progressive | 2016 |
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Attention; Cognition Disorders; Dementia; Double-Blind Method; Executive Function; Female; Humans; Indans; Language; Male; Memory; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Visual Perception | 2011 |
3 other study(ies) available for rasagiline and Cognition Disorders
| Article | Year |
|---|---|
Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice.
Topics: Aging; Animals; Catecholamines; Cognition Disorders; Corpus Striatum; Disease Models, Animal; Exploratory Behavior; Gene Expression Regulation; Indans; Longitudinal Studies; Male; Maze Learning; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Neuroprotective Agents; Receptors, Dopamine D1; Receptors, Dopamine D2; Signal Transduction; Swimming | 2015 |
Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.
Topics: Animals; Brain Infarction; Brain Ischemia; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Indans; Infarction, Middle Cerebral Artery; Male; Maze Learning; Nerve Degeneration; Neuroprotective Agents; Rats; Rats, Wistar; Recovery of Function; Time Factors; Treatment Outcome | 2007 |
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.
Topics: Aging; alpha-Methyltyrosine; Animals; Avoidance Learning; Catalepsy; Cognition; Cognition Disorders; Haloperidol; Hypokinesia; Hypoxia; Indans; Male; Memory; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Motor Activity; Rats; Rats, Wistar | 1998 |